



MARKET RELEASE

26 August 2013

QRxPharma Limited

TRADING HALT

The securities of QRxPharma Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 29 August 2013 or when the announcement is released to the market.

Security Code: QRX

Stephanie Yong
Senior Adviser, Listings Compliance (Sydney)



26 August 2013

ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Attention: Stephanie Yong

Request for Trading Halt – QRxPharma Limited (QRxPharma)

In accordance with Listing Rule 17.1, QRxPharma requests an immediate trading halt in its ordinary securities listed on the ASX.

QRxPharma advises the following, as required under Listing Rule 17.1:

1. the trading halt is necessary as QRxPharma proposes to make an announcement to the market in relation to the results of the New Drug Application review of MOXDUO[®] by the US Food and Drug Administration (**FDA**);
2. QRxPharma requests the trading halt to last until an announcement in relation to the results of the review is released – expected to be prior to the commencement of normal trading on Wednesday, 28 August 2013; and
3. QRxPharma is not aware of any reason why the trading halt should not be granted by the ASX and is not aware of any other information that is necessary to inform the market about the trading halt.

Please contact me if you have any queries.

Yours sincerely

A handwritten signature in black ink that reads 'C. J. Campbell'.

Chris Campbell
Company Secretary

QRxPharma Limited